Bruna Dos Santos Rodrigues1, Takahisa Kanekiyo2, Jagdish Singh3. 1. Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA. 2. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. 3. Department of Pharmaceutical Sciences, School of Pharmacy, College of Health Professions, North Dakota State University, Fargo, ND, USA. Electronic address: jagdish.singh@ndsu.edu.
Abstract
The limitations imposed on brain therapy by the blood-brain barrier (BBB) have warranted the development of carriers that can overcome and deliver therapeutic agents into the brain. We strategically designed liposomal nanoparticles encasing plasmid DNA for efficient transfection and translocation across the in vitro BBB model as well as in vivo brain-targeted delivery. Liposomes were surface modified with two ligands, cell-penetrating peptide (PFVYLI or R9F2) for enhanced internalization into cells and transferrin (Tf) ligand for targeting transferrin-receptor expressed on brain capillary endothelial cells. Dual-modified liposomes encapsulating pDNA demonstrated significantly (P < 0.05) higher in vitro transfection efficiency compared to single-modified nanoparticles. R9F2Tf-liposomes showed superior ability to cross in vitro BBB and, subsequently, transfect primary neurons. Additionally, these nanoparticles crossed in vivo BBB and reached brain parenchyma of mice (6.6%) without causing tissue damage. Transferrin receptor-targeting with enhanced cell penetration is a relevant strategy for efficient brain-targeted delivery of genes.
The limin class="Gene">tations imposed on brainpan> therapy by the blood-brainpan> barrier (BBB) have warranpan>ted the developmenpan>t of pan> class="Gene">carriers that can overcome and deliver therapeutic agents into the brain. We strategically designed liposomal nanoparticles encasing plasmid DNA for efficient transfection and translocation across the in vitro BBB model as well as in vivo brain-targeted delivery. Liposomes were surface modified with two ligands, cell-penetrating peptide (PFVYLI or R9F2) for enhanced internalization into cells and transferrin (Tf) ligand for targeting transferrin-receptor expressed on brain capillary endothelial cells. Dual-modified liposomes encapsulating pDNA demonstrated significantly (P < 0.05) higher in vitro transfection efficiency compared to single-modified nanoparticles. R9F2Tf-liposomes showed superior ability to cross in vitro BBB and, subsequently, transfect primary neurons. Additionally, these nanoparticles crossed in vivo BBB and reached brain parenchyma of mice (6.6%) without causing tissue damage. Transferrin receptor-targeting with enhanced cell penetration is a relevant strategy for efficient brain-targeted delivery of genes.
Authors: Basit Yameen; Won Il Choi; Cristian Vilos; Archana Swami; Jinjun Shi; Omid C Farokhzad Journal: J Control Release Date: 2014-06-28 Impact factor: 9.776
Authors: Benjamin W Neuman; David A Stein; Andrew D Kroeker; Amy D Paulino; Hong M Moulton; Patrick L Iversen; Michael J Buchmeier Journal: J Virol Date: 2004-06 Impact factor: 5.103
Authors: Michael D Buschmann; Abderrazzak Merzouki; Marc Lavertu; Marc Thibault; Myriam Jean; Vincent Darras Journal: Adv Drug Deliv Rev Date: 2013-07-18 Impact factor: 15.470
Authors: Mohamadreza Amin; Mercedeh Mansourian; Peter C Burgers; Bahareh Amin; Mahmoud Reza Jaafari; Timo L M Ten Hagen Journal: Pharmaceutics Date: 2022-02-21 Impact factor: 6.321